Recent

% | $
Quotes you view appear here for quick access.

Sarepta Therapeutics, Inc. Message Board

  • golongin2008 golongin2008 Oct 21, 2012 2:59 PM Flag

    Can the Drug Work on "Regular" MD?

    The hugh market is treating MD throughout the world in adults and children. The SRPT drug seems to work on a very small niche childhood MD. Why does it not work on the others? Or does it?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • From the Oct. 3 article entitled, "DMD: Eteplirsen Results Very Encouraging at 48 Weeks" (viewed from mda.org), it is stated halfway down the article, "Eteplirsen is designed to skip exon 51 of the dystrophin gene, and potentially could benefit about 13 percent of boys with DMD." If 1 in 3600 boys per year worldwide are affected by DMD, then this drug could only potentially benefit 468 of those boys. I, maybe like many others, bought in way too soon with a 30 average and I don't expect to get my money back. I am just hoping for a lesser loss sometime in the future. Good luck to you if you invest in this - a massive risk it is, no doubt.

      Sentiment: Hold

    • Yet another soft bashing a-hle. Don't they ever give up?

      Sentiment: Strong Buy

    • It will work on all 87% of other exons in Duchenne, and should work on other MDs like ALS, SMA, just to name a couple. This exon skipping platform has unlimited potential, as well the anti viral and anti bacterial platforms.
      This company has the potential to revolutionize medicine as we know it. That is why $45,or $7 and change, pre reverse split is still a rediculously low pps. The shorts who are playing this like other biotechs will eventually be crushed. It's not over until the fat lady sings... JMHO

      Sentiment: Strong Buy

 
SRPT
12.35+0.62(+5.29%)Feb 12 4:00 PMEST